Rawlins G A, Wood J M, Bagshawe K D
Br J Cancer. 1976 Dec;34(6):613-8. doi: 10.1038/bjc.1976.221.
Lymphocytes from a total of 161 subjects, including normal controls and patients with malignant and non-malignant conditions, have been investigated for their response to myelin basic protein, using the macrophage electrophoretic mobility (MEM) test. It has been confirmed that there was a high level of association between clinically evident cancer and a positive response. Lymphocytes from 24/25 patients with non-malignant inflammatory and ischaemic diseases also gave positive responses. In 46 patients with breast lumps studied before mastectomy or biopsy, the test was positive in 15/19 cases which proved to be malignant and in 5/27 which proved benign on histological examination. In its present form the test is not sufficiently reliable for the diagnosis of early cancer. Our results suggest that tissue necrosis in malignant and non-malignant conditions may be one of the factors resulting in sensitization to antigenic determinants present in preparations of myelin basic protein. Despite its technical difficulties, the test may provide a means of examing some aspects of immune recall not readily revealed by other test systems.
利用巨噬细胞电泳迁移率（MEM）试验，对总共161名受试者（包括正常对照以及患有恶性和非恶性疾病的患者）的淋巴细胞对髓鞘碱性蛋白的反应进行了研究。已经证实，临床上明显的癌症与阳性反应之间存在高度关联。来自24/25例患有非恶性炎症和缺血性疾病患者的淋巴细胞也给出了阳性反应。在46例乳房肿块患者中，在乳房切除术或活检前进行了该试验，19例经组织学检查证实为恶性的病例中有15例呈阳性，27例经组织学检查证实为良性的病例中有5例呈阳性。以目前的形式，该试验对于早期癌症的诊断不够可靠。我们的结果表明，恶性和非恶性疾病中的组织坏死可能是导致对髓鞘碱性蛋白制剂中存在的抗原决定簇致敏的因素之一。尽管该试验存在技术困难，但它可能提供一种检测其他测试系统不易揭示的免疫回忆某些方面的方法。
